This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bright Near-Term Outlook for Medical Info Systems Industry
by Sweta Jaiswal
The wave of digital transition is helping players in the Zacks Medical Info Systems industry to open up bountiful opportunities for investors.
Syneos Health (SYNH) Down 5.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Syneos Health (SYNH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Syneos Health (SYNH) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Syneos Health (SYNH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
SYNH vs. NXGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
SYNH vs. NXGN: Which Stock Is the Better Value Option?
SYNH vs. CRL: Which Stock Is the Better Value Option?
by Zacks Equity Research
SYNH vs. CRL: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: Gray Television, Syneos, Dollar General, Sabre and Jones Lang
by Zacks Equity Research
Zacks.com featured highlights include: Gray Television, Syneos, Dollar General, Sabre and Jones Lang
5 Cheap GARP Picks With Discounted PEG
by Zacks Equity Research
To make a long-term investment more effective, the principles of both value and growth strategies need to be combined.
Syneos Health (SYNH) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 10.29% and 0.44%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Express Scripts (ESRX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Express Scripts (ESRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Syneos Health (SYNH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SYNH vs. FCHS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SYNH vs. FCHS: Which Stock Is the Better Value Option?
SYNH or FCHS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SYNH vs. FCHS: Which Stock Is the Better Value Option?
SYNH or FCHS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SYNH vs. FCHS: Which Stock Is the Better Value Option?
PRA Health Sciences (PRAH) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
PRA Health Sciences (PRAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SYNH or FCHS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SYNH vs. FCHS: Which Stock Is the Better Value Option?
SYNH or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SYNH vs. HQY: Which Stock Is the Better Value Option?
Syneos Health (SYNH) Beats Q2 Earnings Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 3.33% and -0.98%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
SYNH or FCHS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SYNH vs. FCHS: Which Stock Is the Better Value Option?
SYNH vs. FCHS: Which Stock Is the Better Value Option?
by Zacks Equity Research
SYNH vs. FCHS: Which Stock Is the Better Value Option?
Syneos Health (SYNH): Moving Average Crossover Alert
by Zacks Equity Research
Syneos Health, Inc. (SYNH) is looking like an interesting pick from a technical perspective
SYNH vs. FCHS: Which Stock Is the Better Value Option?
by Zacks Equity Research
SYNH vs. FCHS: Which Stock Is the Better Value Option?
Syneos Health (SYNH) Shares March Higher, Can It Continue?
by Zacks Equity Research
Syneos Health, Inc. (SYNH) has been on the move lately as the stock has risen by 18.9% in the past four weeks, and it is currently trading well above its 20-Day SMA
Envision Healthcare to Go Private With Acquisition by KKR
by Zacks Equity Research
Envision Healthcare to become a private company on acquisition by private equity company KKR.
SYNH vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
SYNH vs. HQY: Which Stock Is the Better Value Option?